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The Asthma Plan published by the French Health Ministry in 2002, the experts conferences edi-
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1484 I. Tillie-Leblond et al.In most so-called developed countries the prevalence of asthma and of allergies has increased
in the last twenty years. Its progress varies according to country and age group: the increased
prevalence of allergy, more specifically of rhinitis and eczema, is most marked in children aged
6-7 year. Theprevalenceof asthma seems tohave reachedaplateau in certain northern countries
or seems to have decreased in 13-14 year olds (Anglo-Saxon countries). There were multiple rea-
sons, generally attributed to changes in life-style. Asthma is the result of an interaction between
a genetic predisposition and the environment, where allergens are present, but also smoking.
The relationships between allergy and asthmaare complex. This conference discussed the var-
ious essential issues that face doctors who treat patients with asthma in their daily practice. The
risk factors, the methods of exploration in children and adults and the specific treatments are,
indeed, essential issues to be evaluated in a frequent pathology that interests a large number
of physicians. The variety of experts is wide, representing pneumology (French Speaking Pneu-
mology Society), the occupational medicine world (FrenchSociety of Occupational Medicine),
the allergic pathology (French Society of Allergology and Clinical Immunology), and patientswith
the patient association ‘‘Asthma & Allergy’’, physicians belonging to the general medicine com-
munity, general hospitals, private hospitals and academic hospitals in France.The proposed
guidelines are aimed at helping practitioners in distinguishing what is established from what re-
mains to be demonstrated and/or assessedwith respect to the differentmodalities for the explo-
ration or treatment of allergic asthma.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
The Asthma Plan on therapeutic education and follow-up of
asthma was published by the French Health Ministry in
2002.73 The inclusion of this disease in the Public Health
Law has been remarkable steps in France during the last
few years.74 The medical community, in particular the
pneumological community, has shown its commitment in
the treatment of this public health problem.
In most developed countries the prevalence of asthma
and of allergies has increased in the last 20 years.75 Their
progress varies according to country and age group: the in-
creased prevalence of allergy, more specifically of rhinitis
and eczema, is most marked in children aged 6e7 year.
The prevalence of asthma seems to have reached a plateau
in certain northern countries or seems to have decreased in
13e14 years old (Anglo-Saxon countries).76 There were mul-
tiple reasons, generally attributed to changes in life-style.
Asthma is the result of an interaction between a genetic
predisposition and the environment, where allergens are
present, but also smoking.
The relationships between allergy and asthma are
complex.77 This conference discussed the various essential
issues faced by doctors who treat patients with asthma in
their daily practice. The risk factors, the methods of explo-
ration in children and adults and the specific treatments
are, indeed, essential issues to be evaluated in a frequent
pathology that interests a large number of physicians. The
variety of experts is wide, representing pneumology
(French Speaking Pneumology Society), the occupational
medicine world (French Society of Occupational Medicine),
the allergic pathology (French Society of Allergology and
Clinical Immunology), and patients with the patient associ-
ation ‘‘AsthmaeAllergy’’, physicians belonging to the gen-
eral medicine community, general hospitals, private
hospitals and academic hospitals in France.
The proposed guidelines are aimed at helping practi-
tioners in distinguishing what is established from what
remains to be demonstrated and/or assessed with respectto the different modalities for the exploration or treatment
of allergic asthma.
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Preamble and methods
The organizing comity, representing the French Speaking
Pneumology Society (SPLF), the French Society of Allergol-
ogy and Clinical Immunology (SFAIC), the French Society of
Occupational Disease (SFMT) and the ‘‘AsthmaeAllergy’’
association, in its first meeting, identified six questions to
be addressed by the experts. A working group was formed in
order to provide answers to each question according to
evidence-based medicine and to propose guidelines. Thebibliography was made up by C. Dumont, responsible for
the medical library at the Medical Faculty in Lille, with an
exhaustive review of the literature (via Medline, Pascal and
the Cochrane Library).
For each question the leaders and the experts wrote long
texts that will be published in a ‘‘news leaflet’’ of the
Revue des Maladies Respiratoires.
Following this work, the organizing comity and the
experts proposed a first version of the recommendations
that were submitted to a vote by all experts and the reading
comity. This vote was taken with three levels of response:
total agreement, less than total agreement and complete
disagreement. The recommendations for which there was
consensus (i.e. is more than 85% ‘‘complete agreement’’
and less than 10% ‘‘complete disagreement’’) were ac-
cepted right away. The other recommendations, for which
no consensus could be reached, were rediscussed in the
plenum meeting with all experts and were again submitted
to a vote. The short text with recommendations was
prepublished on the website of the ‘‘Socie´te´ de Pneumo-
logie de Langue Franc¸aise’’ in order to allow the public of
the session of February 2007, in Lyon, at the 11e French
Speaking Pneumology Congress, to prepare remarks. The se-
lected level of recommendation was that proposed by the
High Health Authority with 3 levels (A, B, C). These recom-
mendations are issued from ‘‘the Agence Nationale d’Accre´-
ditation et d’Evaluation en Sante´: Analyse de la litte´rature
et gradation des recommandations: Guide Me´thodologique.
2000’’.
Level A
Recommendation based on scientific proof supported by
studies with a strong level of evidence. High power,
randomised, comparative studies without major bias,
meta-analyses of randomised studies, decision analyses
based on well controlled studies; exceptionally a Level A
was attributed by the experts to a recommendation based on
less rigorous scientific proof but corresponding to a ‘‘strong
message fort’’ delivered by the experts conference.
Level B
Recommendation based on a scientific presumption sup-
ported by studies of intermediary evidence level; e.g. low
power, randomised, comparative studies, meta-analyses
with questionable methodology, non-randomised but well
conducted studies, cohort studies.
Level C
Based on studies of lower evidence level; e.g. case-control
studies, series of cases.
In case of lack of precision, the proposed recommenda-
tions are based on occupational agreement in the working
group and the reading group (expert advice).
Question 1: What is the role of allergy in the
clinical expression of asthma?
Allergy is not sufficiently taken into account, although it is
associated with 8e63% cases of asthma. The percentage of
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prick test is around 30% in adults.
Sensitization and exposure to allergens in the household
and exterior environment increase the risk of the occur-
rence of asthma symptoms, as well as the risk of exacer-
bations of asthma, both for urgent visits or for Hospital
admissions.1e10
Q1-1: What are the relationships between exposure
to allergens and symptoms of asthma?
The exposure to allergens of cats, cockroaches, mites,
pollen and fungi (Aspergillus, Alternaria and Cladospo-
rium) in sensitive populations is associated with the ap-
pearance of asthma symptoms. The severity of asthma in
sensitive children and young adults depends on the level
of exposure to allergens. The allergological examination
is founded on questioning the patient (where, when and
how do symptoms appear?) and on the results of skin prick
tests. The various life and work sites should be considered.
R1:- It is recommended to question all asthma patients
on their domestic, interior, exterior and occupational
environment and to screen for relationships between
the exposure to an allergen and the occurrence of symp-
toms (Level A).
Question 2: When and how to perform an
allergological exploration?
Q2-1: Is an allergological exploration necessary in
every asthma patient?
Is an allergological enquiry necessary for every asthma
patient older than 3 years? The results of the questioning
will direct the allergological exploration. The allergens to
be tested are adapted to age, clinical history and
environment.11,12
R2:- An allergological exploration is recommended for
every asthmatic patient older than 3 years (Level A).
Is an allergological exploration necessary in all children
less than 3 years old?
R3:- An allergological exploration is recommended in
all infants aged less than 3 years old with persistent and/
or recurring and/or severe respiratory symptoms and/or
requiring continuous anti-asthmatic treatment and/or
associated to extrarespiratory symptoms compatible with
an allergic origin. This includes a history compatible with
food allergy (Level B).Q2-2: Which allergens are to be tested?
What are the allergens to be tested beyond the age of 3
years?
R4:- It is recommended to test aeroallergens: mites,
cats, dogs, tree pollen, grass pollen, herb pollen (ambro-
sia, artemisia, plantain), and the most commonly
involved fungi (Aspergillus, Alternaria, Cladosporium)
(Level A). Other allergens, including cockroaches, should
be tested according to the results of the questioning and
the locoregional data (Level B).Which allergens should be tested before the age of 3
years?
R5:- In children it is recommended to test indoor aero-
allergens (mites, cats, dogs,) and food allergens (cow’s
milk, eggs, peanuts, soja, codfish, nuts) (Level C). Positive
skin prick tests at this age more (Level B) often indicate
a risk factor for persisting respiratory symptoms than
a real allergy. Therefore dietary restrictions are rarely re-
quired but respiratory and allergological follow-up is rec-
ommended (Level C). Other aeroallergens can be tested
according to local ecology and clinical history (Level C).
Q2-3: What is the place of skin prick tests in the
diagnosis of allergy in asthmatic patients?
Skin prick tests are widely used to identify the presence (of
absence) of specific IgE for an allergen on mast cells in the
skin (NP1).12e16
R6:- Skin Prick tests are recommended as first line
tests in the exploration of allergy (Level B).
Testing with a positive control (histamine 10 mg/ml or
codeine phosphate 9%) can help to quantify the response
to allergens and a negative result can indicate an inability
of the skin to respond to the usual mastocyte stimuli. A pos-
itive test with the solvent of the allergens (negative con-
trol) can detect dermographism. Dermographism makes
the tests impossible to assess.13e17
R7:- It is recommended to perform a skin prick test
with a negative control (using the solvent that is used
to dilute the allergens that are tested) and a positive con-
trol (Level A).
R8:- It is recommended to repeat the skin prick tests if
asthma persists in infancy or if the clinical evolution is
not favourable (Level C).
The modification of the reactivity of the skin due to
immunotherapy is very variable and is not correlated to its
efficacy in the case of pneumoallergens.
R9:- It is not recommended to repeat the skin prick
tests for assessing the effectiveness of a specific immuno-
therapy (Level B).
R10:- It is recommended to consider the result of
a skin prick test to an allergen as positive if the diameter
of the wheal is 3 mm or more (negative control with sol-
vent) (Level B).
A positive skin prick test to an allergen reveals a sensi-
tivity to this allergen. The role of this allergen in the
exacerbation of symptoms is reflected in the findings with
respect to this sensitivity and the questioning.12e17
R11:- It is recommended to compare the result of
a skin prick test with an allergen to the findings of the
questioning and to the clinical data (Level B).
Q2-4: What is the place of serial blood tests in the
diagnosis of allergy in asthma patients?
Blood tests should only be requested in the context of the
questioning and of the clinical examination. As for skin
tests, the presence of specific serum IgE for an allergen
does not mean that the patient’s symptoms are related to
the identified allergen. Isolated biological results, indepen-
dent from each other and from the clinical data, cannot
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a given patient.18e22
Multiallergenic tests can suggest an allergic origin of the
symptoms but the levels of sensitivity and specificity are
very variable depending on the tests, the used allergens
and the techniques. Multiallergenic tests with a specific
semi-quantitative response can result in non-specific fixa-
tions and the agreement with skin tests is variable. In some
patients, factors affecting the skin reactivity may be
present.23 Skin test wheals increase in size from infancy
to adulthood, and are sometimes negative before 3 months.
It declines after the age of 50. Eczema may diminish the
skin reactivity to histamine. Some drugs such as anti-H1
histamines, ketotifen, imipramines, phenothiazines and
tranquilizers, long-term corticosteroids, clonidine or dopa-
mine may suppress skin test responses. In such conditions,
skin prick tests are not relevant and blood tests should be
performed.13
R12:- If skin prick tests are not possible as first line
examination, a multiallergenic test is recommended
(Level C). In case of a positive result, an allergological
exploration should be carried out (Level C).
Should total serum IgE be assayed in the diagnosis of
allergy?
Total IgE is an inadequate test to screen for allergy in
asthma patients.24
R13:- Assayof serum IgE is in practice not recommended
in asthmatic patients, except in two clinical situations:
prior to initiating anti-IgE treatment and when allergic
bronchopulmonary aspergillosis is suspected (Level A).
R14:- Repeated dosing of total IgE is not recommended
in the follow-up of allergic asthma (Level A), except
when allergic bronchopulmonary aspergillosis is diag-
nosed (Level C).
Assay of specific serum IgE must be performed using a
validated method. The results are expressed in KU/l. The
specificity and the sensitivity are estimated between 85-95%
and the correlation between specific IgE and the prick test
is 90e95% with recent immunoenzymatic techniques.25
R15:- It is not recommended to perform a dosing of spe-
cific serum IgE for a aeroallergen as a first line examination
in daily practice (Level A). It is recommended to carry out
this dosing in cases of disagreement between the clinical
symptoms and the results of skin prick tests or when skin
prick tests cannot be carried out or assessed (Level B).
Serum eosinophilia is observed in both allergic and non
allergic asthma. It is dependent on the severity of the un-
treated asthma. It is not a determining factor for allergy.26,27
R16:- It is not recommended to screen for serum
hypereosinophilia as a first line test in asthma patients
(Level B).
Question 3: Is asthma a risk factor for
anaphylaxis?
Q3-1: Is allergic asthma a risk factor for
allergy to myorelaxants?
Myorelaxants are responsible for more than 50% of the
anaphylactic accidents in anaesthesia. The question is
whether the presence of atopy, as is by definition thecase in patients with allergic asthma, increases the risk of
anaphylactic or anaphylactoid accidents with curare. In
a French epidemiologic study no difference in atopic profile
or presence of asthma was observed in cases of anaphylac-
tic or anaphylactoid manifestations to curare.28,29
Allergic asthma is not a risk factor for anaphylaxis to
curare.
R17:- It is not recommended to systematically carry
out tests for curare in patients with allergic asthma
having to undergo general anaesthesia (Level B).
Q3-2: Is allergic asthma a risk factor for
vaccination accidents?
The risk of anaphylaxis following vaccination is low.30
Sensitivity to eggs is a risk factor for allergic accidents to
vaccines containing egg protein. In asthma patients sensi-
tized to eggs, without clinical history of allergy to eggs,
there is no evidence that asthma is a risk factor for allergic
accidents with vaccines containing egg protein.
R18:- In patients sensitized to egg, without a clinical
history of allergy to eggs, an allergological exploration
is only recommended in patients who already had allergic
reactions following vaccination against influenza or
yellow fever or another vaccine containing egg protein
(Level C).
Q3-3: Is allergic asthma a risk factor for
allergy to penicillins?
Atopy does not increase the risk of developing an allergic
reaction to beta-lactam antibiotics. Allergic asthma does
not increase the risk of reactions to penicillins (expert
opinion). Allergic asthma does not increase the risk of
secondary reactions in diagnostic skin tests with beta-
lactam antibiotics.31,32
R19:- It is not recommended to contraindicate the
administration of beta-lactam antibiotics in patients
with allergic asthma, except in cases of documented
allergic antecedents to this class of antibiotics. In case
of a suspected history of allergy to penicillin, an explora-
tion is necessary in order to confirm or exclude allergy to
penicillin, prior to any prescription of antibiotics of this
class. In case of documented allergy to penicillin, all
antibiotics belonging to this class are to be avoided (Level
C). The choice of a cephalosporin will be guided by skin
tests with the cephalosporin (Level B).
Q3-4: Is allergic asthma a risk factor for
allergy to Hymenoptera?
In the general population asthma and atopy are no risk
factors for anaphylactic reactions to stings by
hymenoptera.33
In bee farmers with an allergy to hymenoptera, rhino-
conjunctivitis and allergic asthma increase the risk of
developing systemic reactions to a bee sting.34
R20:- It is recommended to take the same precautions
when practicing skin tests or desensitization for
hymenoptera in patients with asthma or without (ex-
perts’ opinion). If the asthma is not controlled, the
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dose) to hymenoptera should be postponed (Level C).
Particular precautions should be taken in bee farmers
asthmatics (expert opinion).
Q3-5: Is allergic asthma a risk factor for anaphylaxis
with iodine containing contrast media (ICCM)?
Epidemiological studies show an increase in the incidence
of severe reactions (dyspnoea, hypotension, loss of con-
sciousness, cardiac arrest) to ICCM in a subpopulation with
asthma, compared to the general population.
R21:- It is recommended to inform the radiologist of
the asthma before any examination requiring the
injection of iodine containing contrast agents (Level A).
If the asthma is not controlled, the injection of iodine
containing contrast agents should, if possible, be post-
poned (Level C).
The incidence of reactions is three times higher with
ionic ICCM than with non-ionic ICCM. In 1998 the American
College of Radiology (Manual on Contrast Media) recom-
mended the use of low osmolality iodine containing
contrast media in patients with asthma. In patients with
uncontrolled asthma, the benefit/risk ratio should be
considered prior to proposing en examination with iodine
containing contrast media.
R22:- In patients with asthma it is recommended to
use low osmolality iodine containing contrast media
(Level C).
Premedication based on corticoids and/or antihistaminic
drugs is often prescribed. Anaphylactic reactions to iodine
containing contrast media are rare. The usefulness of
premedication prior to using iodine containing contrast
agents is not demonstrated, neither in a random popula-
tion, nor in patients with atopy.35
R23:- It is not recommended to use premedication in
asthma patients prior to injecting iodine containing
contrast media (Level C).
Q3-6: Is allergic asthma a risk factor for
anaphylactic shock induced by food allergy?
The most severe manifestations of food allergy in children
and adults occur in patients with asthma. In the event of
anaphylactic shock, death of respiratory origin is frequent.
Asthma increases the risk of fatal accidents. An analysis of
small cohort and case reports in patients with a history of
anaphylactic shock after the ingestion of food e in children
and adolescents e shows that the majority suffers from
asthma. Asthma is a risk factor for the development of
anaphylactic shock. The risk is higher in children, adoles-
cents and young adults. All foodstuffs can be involved, but
some, such as peanuts, tree-nuts and sesame, are more
frequently involved. Poorly controlled asthma is a risk factor.
Alcohol, stress (stress anaphylaxis) or the use of aspirin or
NSAIDs are also risk factors or contribute to severity.
Anaphylactic shock is more severe in asthmatic patients.36
R24:- In asthmatic patient with food allergy, it is
recommended to eliminate the responsible allergen, to
have an emergency kit and an allergy card in order to
prevent and treat anaphylactic shock (Level A).Question 4: What is the place of the physical
examination in allergic patients with asthma?
Q4-1: Should an ENT examination be carried
out in all allergic patients with asthma?
In about 80% of cases rhinitis are associated to asthma.
Controlling the disease is more difficult in patients with
asthma who also suffer from intermittent rhinitis or
persistent rhinitis. Screening for ENT involvement is neces-
sary in patients with asthma. Questioning the patient has an
important diagnostic value in rhinitis and the absence of
ENT symptoms has a good negative predictive value.37e41
Specific treatment of rhinitis can have a beneficial
effect on asthma.42
R25:- It is recommended to question the patient in
order to screen for concomitant rhinitis in a patient with
allergic asthma: anterior and/or posterior secretion, anos-
mia, obstruction and nasal itching and sneezing (Level B).
R26:- It is recommended to treat rhinitis in order to
improve the control of associated asthma (Level B).
A CT scan of the sinuses has a good negative predictive
value for the diagnosis of sinusitis (91%) or of polyps (97%).
This is only 24% for rhinitis. In the three cases the
examination has a positive predictive value of less than
40%. When sinusitis is suspected, CT scan confirmation
should be recommended in adult when available.43
R27:- It is not recommended to carry out an imaging
examination of the sinuses (X-ray and CT scan) as a first
line examination or in order to detect rhinitis in a patient
with allergic asthma (Level B).
Q4-2: Should atopic dermatitis (AD) be screened
for in all patients with allergic asthma?
The incidences of allergic asthma and of AD increase in
parallel. The increased risk of developing asthma in case of
AD is controversial. AD and asthma frequently coexist in
young children.44 Certain studies suggest a correlation be-
tween the severity of asthma and of AD. The diagnosis of
AD is a clinical one and is based on the criteria of the United
Kingdom Working Party (UKWP) (pruritus associated to at
least 3 of 5 criteria, based on the antecedents and the ap-
pearance of the skin). These manifestations should be
screened for in children with asthma (experts opinion).
R28:- It is recommended to screen for AD by question-
ing and by a clinical examination in each child with aller-
gic asthma (Level A).
Question 5: Are there specific treatments for
allergic asthma?
Q5-1: What is the place of a specific
immunotherapy (SIT) in the treatment
of allergic asthma?
A subcutaneous specific immunotherapy against mites or
pollen is effective against the symptoms of asthma, the use
of drugs and the level of bronchial hyperreactivity.
Improvement in antigen sensitivity assessed by provocation
Asthma and allergy 1489test was demonstrated in patient sensitized to ragweed
under specific immunotherapy. This is in favour of bron-
choprotective effect of SIT. The clinical effects of a specific
subcutaneous immunotherapy (SIT) can persist until several
years after discontinuation of the treatment. Specific
immunotherapy (SIT) prevents acquiring new sensitizations
to pneumoallergens in children. Immunotherapy in patients
with rhinitis reduces the risk of asthma. The effectiveness
of sublingual desensitization (SLIT) on the symptoms of
asthma has been demonstrated in certain clinical studies
including a subgroup of patients with asthma, and in
specific studies with asthma. It may represent an alterna-
tive treatment for subcutaneous SIT.45e50
R29:- It is not recommended to carry out SIT with
more than two allergens belonging to different families
(Level C).
SIT can only be used for allergens with a demonstrated
effectiveness in well controlled clinical studies. In practice,
for asthma, this is limited to mites and pollens of grass,
birch and Ambrosia.
R30:- It is recommended to use SIT with allergens with
a demonstrated effectiveness and safety (mites, pollen of
grass, birch and Ambrosia) (Level B).
The incidence of systemic reactions to SIT is estimated
at 1 in 1250e2206 injections (most often local reactions,
the incidence of death is 1 in 1e2 million injections).
Patients with asthma have a higher risk of presenting
serious systemic manifestations, particularly if the asthma
is not controlled or if the FEV1 is less than 70% of the pre-
dicted value.
R31:- In view of the risk of side-effects, particularly of
bronchospasm, more specifically in the phase of increas-
ing doses, it is recommended to propose SIT only in
patients with controlled asthma with a nearly normal
ventilatory function (FEV1 more than 70% of the
expected value) (Level A).
R32:- It is recommended to perform the injections un-
der immediate supervision by a physician, after examina-
tion of the clinical condition, supervision of the patient
in the physician’s office for at least half an hour following
the injection, availability of treatment of anaphylactic
reactions (in particular injectable epinephrine) (Level A).Q5-2: What is the place of anti-IgE in the
treatment of allergic asthma?
A recently published meta-analysis demonstrated the
effectiveness of omalizumab in the treatment of severe
asthma of allergic origin, particularly in allowing a 50%
reduction of the daily dose of inhalation corticosteroids or
a 45% reduction of asthma exacerbations compared to
placebo.
In cases of severe asthma anti-IgE are effective in
reducing the frequency of exacerbations, the symptoms
and the quality of life. It is, however, impossible, at an
individual scale, to define predictive factors of effective-
ness of this treatment.51
R33:- It is recommended to limit treatment with anti-
IgE to poorly controlled, severe, persistent allergic
asthma (age more than 12 years), in addition to optimal
conventional treatment (Level A).What assessment is recommended before deciding on
a treatment with anti-IgE?
It should only be proposed after a complete assessment
of the patient with evaluation of asthma and allergic
status.
R34:- It is recommended to confirm the diagnosis of
the severity and the level of control of asthma (assess-
ment of control with questionnaire and pulmonary func-
tion tests), to ensure treatment of aggravating factors
and to control the adhesion to treatment before propos-
ing treatment with an anti-IgE (Level B).
Q5-3: What is the place of the avoidance of
allergens in the treatment of allergic asthma?
The assessment of the effectiveness of measures to
eliminate aeroallergens from the domestic environment
mainly concerns mites. The publication of a meta-analysis,
surveying patients with a often poorly defined allergolog-
ical diagnosis and using only one single method for the
elimination of mites for variable periods of time, revealed
that, for mites, the effectiveness of this method was not
established. The effectiveness of overall elimination was
established in children with severe persistent allergic
asthma. There was a correlation between clinical improve-
ment and the extent of reducing the allergen. In adults,
several limited studies have shown the effectiveness of the
elimination of mite allergens.52e54 Although complete
avoidance of allergens in high altitude was found to
improve the control of asthma, most avoidance measures
for mites, animal danders and cockroaches are poorly
effective. In inner cities, home-based environmental inter-
ventions were found to improve asthma.
Should measures for the elimination of allergens be
proposed?
R35:- It is recommended to eliminate the responsible
allergens, as much as possible, for children suffering
from allergic asthma (Level B). Although there are not,
as yet, sufficient data with adults suffering from allergic
asthma, the avoidance of allergens is recommended
(Level B).
Measures against mites
Reducing the relative humidity, using anti-mite covers,
washing and drying tissues, weekly vacuum cleaning and
changing bed linen should eliminate mites. The nature of
the floor (vinyl or wood) could minimise mite content
within bedroom. The global allergen reduction requires
the use of anti-mite covers and, if needed, a complete
change of bed linen, regular washing of bedroom textile
(every 3 months) and weekly vacuum cleaning following an
assessment of the mite load. The cost of these measures is
high and is not always feasible in normal practice.
R36:- When elimination is proposed, the most com-
plete elimination of mites from the bedroom is recom-
mended in cases of mite induced allergic asthma,
dependent on the allergenic load (Level C).
Allergens from cats, dogs and other pets
The concomitant use of air purification and a vacuum
cleaner with HEPA filters results in a 98% reduction of the
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measures do not affect the symptoms of asthma.55
R37:- It is recommended to eliminate cats, dogs or
other pet animals in cases of animal induced allergic
asthma or to keep the animal outside the house (Level C).
When elimination is not possible, no other technique
has been able to demonstrate its effectiveness (Level C).
Should the environmental allergenic load be assessed?
There are two categories of dosing methods: domestic
tests for use in daily practice by physicians, paramedics or
the patient, and methods requiring a specialized laboratory
and usually limited to use in epidemiologic research. This
question only addresses domestic tests. Acarex-test mea-
sures the exposure to mite allergens in a semi-quantitative
way. Rapid-test is a semi-quantitative (3 classes) screening
for mite allergens.
R38:- It is recommended to assess the allergenic mite
load in the house before proposing elimination measures
(Level C).Question 6: What are the interactions between
allergic asthma and the occupational
environment?
Q6-1: What is the fraction of the asthma risk
attributable to occupational environment?
Occupational asthma (OA) is characterized by inflamma-
tion of the airways, variable bronchial obstruction and
non-specific bronchial hyperresponsiveness due to causes
and situations attributable to a particular occupational
environment.56 OA should be distinguished from asthma
that is aggravated by work, defined as persistent or
recently appeared asthma, with manifestations that are
exacerbated but not induced by the exposure to occupa-
tional nuisances.
The attributable risk is calculated based on the relative
risk, measuring the consequences of the presence of a risk
factor on the occurrence of the disease compared to the
absence of that factor. The fraction of the asthma risk
attributable to the occupational environment can be
defined as the number of cases of asthma that could be
avoided in the absence of exposure to the sensitizing and/
or irritating agents on the workplace. It can be assessed by
studies in the general population (transversal studies,
caseecontrol studies, cohort studies). The fraction of the
risk attributable to occupational exposure is of the order of
9e15%.57e62
R39:- It is recommended to question all asthma
patients on the chronological relationship between their
symptoms and occupational exposure, particularly in
individuals exposed to agents known to be responsible
for occupational asthma (Level A).Occupations at risk
Many occupations are associated to an increased risk of
asthma. Programmes for voluntary surveillance and
studies based on registers give a somewhat different
picture. The highest incidences of OA are observed in
bakers and spray painters.63e65 High incidences werealso reported in hairdressers, welders and in the plas-
tics industry. Nearly 300 aetiological agents of OA were
registered.66,67 A regularly updated Internet site lists
causal agents and occupations at risk (www.asmanet.
com).
R40:- It is recommended to thoroughly search for
a occupational origin in a patient with asthma having
a high-risk occupation: cleaning occupations, agriculture,
bakers, painters, hairdressers, health care workers,
welders (Level B).Q6-2: How can occupational origin of asthma
be diagnosed?
The diagnosis of asthma, that was suspected based on
clinical manifestations, must necessarily be confirmed
by respiratory function tests demonstrating a reversible
airway obstruction and/or a non-specific bronchial
hyperresponsiveness.
The positive predictive value of a suggestive clinical
history is poor.68 The sensitivity of interrogating the patient
has hardly been evaluated. The interrogation can be incon-
clusive, particularly in cases of long existing asthma.
Including questions about the existence of wheezing at
work could improve the quality of the interrogation.69
R41:- Due to the lack of specificity of the interrogation
and the potentially severe consequences of the disease
on the occupation situation, it is recommended to con-
firm the diagnosis of occupational asthma by objective
methods (Level B).
Are immunological tests necessary in cases of
suspected occupational asthma?
Skin prick tests are available for high molecular weight
allergens of animal or vegetable origin. Dosing specific IgE is
possible for most high molecular weight occupational
allergens. It is only possible for a very small number of
low molecular weight chemical allergens. The sensitivity of
specific IgE is low for low molecular weight agents. The
sensitivity of specific IgE is good for high molecular weight
agents and their negativity practically rules out the in-
volvement of the tested agent for asthma.
R42:- If the responsibility of a high molecular weight
occupational allergen (animal or vegetable protein) is
suspected, it is recommended to examine the relevance
to this allergen with a skin prick test and/or dosing of spe-
cific serum IgE (Level B).
Has monitoring of the peak expiratory flow rate (PEFR)
a place in the diagnosis of occupational asthma?
The sensitivity and the specificity of the PEFR, compared
to specific inhalation challenges (SICs) tests or a combina-
tion of examinations, are generally of the order of 70%. The
diagnostic reliability is affected by the number of daily
measurements (nZ 4) and the duration of the observation
period (NZ 4 months).70,71
R43:- Monitoring the peak expiratory flow rate (PEFR)
or FEV1 is recommended in case of suspected occupa-
tional asthma (Level B).
R44:- It is recommended to interpret the results of the
PEFR taking into account the episodes of exposure, the
number and the duration of the measurements the treat-
ment and the patient’s cooperation (Level C).
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the diagnosis of occupational asthma?
Specific inhalation challenge tests are often presented
as the gold standard for the diagnosis of occupational
asthma.72 There are, however, important limitations. The
tests are time consuming, expensive, and potentially dan-
gerous. The availability of these examinations is limited
to few asthmatic centers.
R45:- It is recommended to carry out a specific inhala-
tion challenge tests in specialized centers if the diagnosis
of occupational asthma is not possible with other diag-
nostic means (Level C).
When should the exploration for occupational asthma
be carried out?
The sensitivity of the diagnostic tests is reduced if the
individual is no longer exposed to the agent that he is
sensitive to.
R46:- It is recommended to carry out the investigation
at a time of occupational activity, except if the severity
or the control of the asthma requires immediate elimina-
tion of the allergen (Level B).
Who should carry out the exploration for occupational
asthma?
No single tests allows for a diagnosis of occupational
asthma. Each of them can result in false positive and/or
false negative results and the criteria for positive result
sometimes remain largely subjective.
R47:- It is recommended that the interpretation of
the results is done by a physician experienced in occu-
pational asthma management (Level C).Q6-3: What drugs should specifically be
proposed in occupational asthma?
R48:- It is recommended to use drug treatments in the
same way as for not occupational asthma (Level C).
Should a specific immunotherapy be proposed for
occupational asthma?
There are very few studies with specific immunotherapy
for occupational asthma. The best-documented studies are
with subcutaneous or sublingual immunotherapy in health
care workers with latex allergy. This is a high-risk treat-
ment because of the observed systemic reactions. There
are a few publications on studies with desensitization to
wheat flower, maple tree and rats, and these studies
included very small number of subjects and/or
uncontrolled.
R49:- It is recommended not to carry out a specific
immunotherapy in cases of occupational asthma
(Level B).
Should discontinuation of exposure to the causal agent
be proposed?
There is a general consensus that early and complete
discontinuation of exposure to the causal agent is the
best treatment for occupational asthma, but a discontin-
uation of exposure is often obtained at the price of
serious social consequences, particularly in France,
because of the absence of adequate accompaniment
for the specific problem of occupational asthma. The
long-term effects of reducing the exposure on the
evolution of OA have been studied and the results arecontradictory. They seem better for asthma induced by
latex, platinum salts or trimellitic anhydride than for
isocyanates. Complete discontinuation of the exposure
remains the best treatment of occupational asthma, but
reducing the exposure may represent an acceptable
compromise in certain cases in order to limit the
negative socioeconomic consequences.
R50:- It is recommended, as far as possible, to remove
the worker from the causal agent (Level B).Acknowledgements
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